In this episode of #ImmunoLogic, the cohosts speak with Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at Penn Medicine, University of Pennsylvania Health System, about the risk-benefit ratio of #CART. #celltherapy Listen now: https://lnkd.in/eh29m2qp
CGTLive
在线音视频媒体
Cranbury，New Jersey 3,021 位关注者
CGTLive? delivers the latest news and expert insights on cell, gene, regenerative, and engineered medicines.
关于我们
CGTLive? delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.
- 网站
-
https://www.cgtlive.com/
CGTLive的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 501-1,000 人
- 总部
- Cranbury，New Jersey
- 类型
- 私人持股
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury，08512
动态
-
ICYMI: With regard to safety, RGX-202 was characterized as “well-tolerated" as of the February 21, 2025 data cutoff. #MDAconference #genetherapy #Duchenne REGENXBIO Muscular Dystrophy Association Read more: https://hubs.li/Q03dP2qY0
-
“What we're doing is truly changing how the immune system communicates so that it doesn't mount an attack on the transplanted organ." -David-Alexandre C. Gros, MD (Eledon Pharmaceuticals, Inc.) #KidneyDisease #KidneyTransplant #genetherapy $ELDN Watch now: https://hubs.li/Q03dNZr00
-
In observance of #NationalColorectalCancerAwarenessMonth, held annually in March, we took a look back at news in #celltherapy for #colorectalcancer indications. Colorectal Cancer Alliance Read more: https://hubs.li/Q03dqm7h0
-
Three patients treated with DT-DEC01 showed improvements in various functional tests, including echocardiography, arm movements, grip strength, and spirometry after 12-24 months of treatment. #celltherapy #MDAconference #MuscularDystrophy Muscular Dystrophy Association Dystrogen Therapeutics Read more: https://hubs.li/Q03cYzfl0
-
In honor of #MSawarenessMonth, observed annually in March, CGTLive? is taking a look back at the progress that has been made in #celltherapy for #MultipleSclerosis over the past year. #MSawareness Read more: https://hubs.li/Q03cYpjm0
-
#BREAKING: The FDA has approved Alnylam Pharmaceuticals's subcutaneous RNA interface therapy vutrisiran, marketed as #Amvuttra, for the treatment of ATTR-CM. #cardiomyopathy #amyloidosis #RNA FDA Read more: https://hubs.li/Q03cRWr-0
-
ICYMI: OAV101 IT is differentiated from the FDA-approved version of Zolgensma, which is delivered systemically, in that it is delivered directly to the spine. #MDAconference #SpinalMuscularAtrophy #genetherapy Novartis Muscular Dystrophy Association Read more: https://hubs.li/Q03cRtPk0
-
ICYMI: Sarepta Therapeutics said that the patient had recently experienced a cytomegalovirus infection that the investigators noted may have contributed to the patient’s death. #genetherapy #Duchenne #MuscularDystrophy Read more: https://hubs.li/Q03cRh750
-
With regard to safety, RGX-202 was characterized as “well-tolerated" as of the February 21, 2025 data cutoff. #MDAconference #genetherapy #Duchenne REGENXBIO Muscular Dystrophy Association Read more: https://hubs.li/Q03cLVrG0